The FDA has approved Alimta (pemetrexed injection, from Eli Lilly) as maintenance therapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.